Evidence map›Paper›PMID 30988614›Full record

ArticleInternational journal of nanomedicine2019

DIBc, a nanochelating-based nano metal-organic framework, shows anti-diabetic effects in high-fat diet and streptozotocin-induced diabetic rats.

Saideh Fakharzadeh, Somayeh Kalanaky, Maryam Hafizi, Mohammad Hassan Nazaran, Homeira Zardooz

Abstract read
In one paragraph

Article in International journal of nanomedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Trial
  2. The role of nano-chelated iron on anatomical and biochemical characteristics and concentration of mineral nutrients in lettuce (Physiology and molecular biology of plants : an international journal of functional plant biology · 2024
    Article
  3. Review
  4. Article
  5. Review
  6. Ameliorative Effects ofNutrients · 2022
    Article
  7. Article
  8. GreenJournal of diabetes research · 2020
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Saideh FakharzadehDepartment of Physiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran, homeira_zardooz@sbmu.ac.ir.
Somayeh KalanakyDepartment of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran, mnazaran@nanochelatingtechnology.com.
Maryam HafiziDepartment of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran, mnazaran@nanochelatingtechnology.com.
Mohammad Hassan NazaranDepartment of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran, mnazaran@nanochelatingtechnology.com.
Homeira ZardoozDepartment of Physiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran, homeira_zardooz@sbmu.ac.ir.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsDespite daily increase in diabetic patients in the world, currently approved medications for this disease, at best, only reduce its progression speed. Using novel technologies is a solution for synthetizing more efficient medicines. In the present study, we evaluated anti-diabetic effects of DIBc, a nano metal-organic framework, which is synthetized based on nanochelating technology.

methodsHigh-fat diet and streptozotocin-induced diabetic rats were treated by DIBc or metformin for 6 weeks.

resultsDIBc decreased plasma glucose, triglyceride, cholesterol, high-density lipoprotein, and low-density lipoprotein compared with diabetic and metformin groups. In DIBc-treated rats, significant homeostasis model assessment of insulin resistance index, malondialdehyde, and tumor necrosis factor-α decrease was observed. H&E staining showed increased islet number and area in DIBc-treated rats compared with diabetic controls.

conclusionThe results showed anti-diabetic effects of nanochelating-based framework. So DIBc, as a nano structure, has the capacity to be evaluated in future studies as a novel anti-diabetic agent.

Indexed as

AnimalsBlood GlucoseDiabetes Mellitus, ExperimentalDiet, High-FatDrinking BehaviorFeeding BehaviorHemoglobinsInsulinInsulin ResistanceIronLipidsLiverMaleMalondialdehydeMetal-Organic FrameworksNanoparticlesBlood GlucoseHemoglobinsInsulinIronLipidsMalondialdehydeMetal-Organic FrameworksStreptozocinTumor Necrosis Factor-alphadiabetesDIBchigh-fat dietmetal organic frameworknanochelating technologystreptozotocin

Identifiers

PMID30988614
PMCPMC6443220

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.